Research location
Golden Valley
Minnesota, United States
Advertisement
Research activity in Golden Valley
Minnesota, United StatesCureCurrent currently publishes aggregate city-level research activity for this location: 99 trials and 103 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Golden Valley
99 linked trials · page 2 of 2Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF EpisodesNCT02240030 · 2014-11-01 · 1 site observation
COMPLETED
Use of Decision Aids in Clinical EncountersNCT02136199 · 2014-09-01 · 1 site observation
COMPLETED
Open-Label Safety Study of ADS-5102 in PD Patients With LIDNCT02202551 · 2014-07-01 · 1 site observation
COMPLETED
Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)NCT02159573 · 2014-07-01 · 1 site observation
COMPLETED
ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)NCT02136914 · 2014-05-01 · 1 site observation
COMPLETED
Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their HomesNCT02038959 · 2014-03-01 · 1 site observation
COMPLETED
Rebif® Rebidose® Versus Rebiject II® Ease-of-UseNCT02019550 · 2014-03-01 · 1 site observation
COMPLETED
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's DiseaseNCT01968460 · 2013-12-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1)NCT01963611 · 2013-10-01 · 1 site observation
TERMINATED
Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMSNCT01903291 · 2013-08-01 · 1 site observation
COMPLETED
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) PatientsNCT01895335 · 2013-06-01 · 2 site observations
COMPLETED
Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United StatesNCT01873417 · 2013-05-01 · 1 site observation
COMPLETED
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's DiseaseNCT01560754 · 2012-10-01 · 1 site observation
UNKNOWN
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01412333 · 2011-09-20 · 1 site observation
COMPLETED
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple SclerosisNCT01247324 · 2011-08-31 · 1 site observation
COMPLETED
Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying TherapiesNCT01442194 · 2011-08-01 · 1 site observation
COMPLETED
Pioglitazone in Early Parkinson's DiseaseNCT01280123 · 2011-03-01 · 1 site observation
COMPLETED
Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)NCT01060878 · 2010-11-01 · 1 site observation
COMPLETED
BG00012 Phase 2 Combination Study in Participants With Multiple SclerosisNCT01156311 · 2010-06-01 · 1 site observation
COMPLETED
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseaseNCT01096186 · 2010-03-01 · 1 site observation
COMPLETED
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With NatalizumabNCT01070836 · 2010-03-01 · 1 site observation
COMPLETED
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's DiseaseNCT01049984 · 2009-12-01 · 1 site observation
COMPLETED
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa TherapyNCT00957918 · 2009-10-01 · 1 site observation
COMPLETED
Parkinson's Foundation Quality Improvement InitiativeNCT01629043 · 2009-07-01 · 1 site observation
COMPLETED
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease SubjectsNCT00936676 · 2009-07-01 · 1 site observation
COMPLETED
Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson DiseaseNCT00909545 · 2009-07-01 · 1 site observation
COMPLETED
Safety of Urate Elevation in Parkinson's DiseaseNCT00833690 · 2009-06-01 · 1 site observation
COMPLETED
A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseaseNCT00880620 · 2009-04-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Fipamezole in Treatment of Motor Dysfunctions in Parkinson's DiseaseNCT00559871 · 2007-10-01 · 1 site observation
COMPLETED
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 TrialNCT00649792 · 2007-08-01 · 1 site observation
COMPLETED
Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal PatchNCT00522379 · 2007-07-01 · 1 site observation
COMPLETED
Study of Fampridine-SR Tablets in Multiple Sclerosis PatientsNCT00483652 · 2007-05-01 · 1 site observation
COMPLETED
NET-PD LS-1 Creatine in Parkinson's DiseaseNCT00449865 · 2007-03-01 · 1 site observation
TERMINATED
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine AgonistsNCT00443872 · 2007-03-01 · 1 site observation
COMPLETED
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson DiseaseNCT00335166 · 2006-11-01 · 1 site observation
COMPLETED
Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor FluctuationsNCT00368108 · 2006-08-01 · 1 site observation
COMPLETED
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 TrialNCT00648908 · 2006-06-01 · 1 site observation
COMPLETED
Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's DiseaseNCT00125138 · 2005-07-01 · 1 site observation
COMPLETED
Study of Oral Fampridine-SR in Multiple SclerosisNCT00127530 · 2005-05-01 · 1 site observation
COMPLETED
Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRxNCT00211887 · 2005-01-01 · 1 site observation
COMPLETED
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated DyskinesiaNCT00105521 · 2004-09-30 · 1 site observation
COMPLETED
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple SclerosisNCT00078338 · 2004-02-16 · 1 site observation
COMPLETED
Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple SclerosisNCT00654927 · 2003-11-01 · 1 site observation
COMPLETED
A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved DoseNCT00202982 · 2003-08-01 · 1 site observation
COMPLETED
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MSNCT00206648 · 2003-03-01 · 1 site observation
COMPLETED
Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.NCT00036218 · 2001-12-01 · 1 site observation
COMPLETED
Open Label Sumanirole Study of Safety, Tolerability, and Therapeutic Response In Patients With Parkinson's DiseaseNCT00036205 · 2000-08-01 · 1 site observation
TERMINATED
A Study of Glaucoma or Ocular Hypertension in Patients Within the United StatesNCT00800267 · 1997-07-01 · 1 site observation
COMPLETED
Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple SclerosisNCT02807285 · 1 site observation
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.